Purchase Order 36C24224P1735
- Not listed
- This federal contract award, valued at $12,580.72, was issued by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 2 (VISN 2) to the prime contractor, Walgreens Specialty Pharmacy, LLC (doing business as Walgreens). The contract is for the delivery of the medication Jynarque (tolvaptan), which is used to treat autosomal dominant polycystic kidney disease. This is a firm fixed-price purchase order with a completion date of February 13, 2025. Walgreens Specialty...
- This federal contract award, with ID 36C24225P0619, was issued by the Veterans Health Administration (VHA) under the Department of Veterans Affairs (VA) to Walgreens Specialty Pharmacy, LLC, a subsidiary of the Walgreens retail pharmacy chain. The $13,242.99 firm fixed-price purchase order is for the supply of the medication Jynarque (tolvaptan), which is used to treat autosomal dominant polycystic kidney disease. The contract has an ultimate completion date of May 19, 2025 and was awarded on...
- This is a federal contract award with the ID 36C24225P0419, issued by the U.S. Department of Veterans Affairs (VA) to the prime contractor Walgreens Specialty Pharmacy, LLC (doing business as Walgreens). The contract is for the supply of the pharmaceutical product Jynarque (tolvaptan) 45mg/15mg tablets, which is used to treat autosomal dominant polycystic kidney disease. The contract is a firm fixed price purchase order with a ceiling value of $13,242.99 and an ultimate completion date of...
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) to Walgreens Specialty Pharmacy, LLC, a subsidiary of the Walgreens retail pharmacy chain. The contract is for the supply of the medication Jynarque (tolvaptan), which is used to treat autosomal dominant polycystic kidney disease. The contract has a ceiling value of $83,000.32 and a performance period ending on September 30, 2021. The contract is not set aside for any specific business type....
- This federal contract award, valued at $12,580.72, was issued by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 2 (VISN 2) to Walgreens Specialty Pharmacy, LLC, a division of the Walgreens retail pharmacy chain. The contract is for the delivery of the specialized pharmaceutical product Jynarque (tolvaptan), which is used to treat autosomal dominant polycystic kidney disease. This is a firm fixed-price purchase order contract with a period of performance ending...
- This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs to Walgreens Specialty Pharmacy, LLC, a subsidiary of the Walgreens retail pharmacy chain. The contract is for the delivery of Jynarque (tolvaptan) 45/15 mg tablets, a medication used to treat autosomal dominant polycystic kidney disease. The contract has a ceiling value of $13,242.99 and a performance period ending on December 4, 2025. The contract was awarded on September 4, 2025 and is not...
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration, specifically the Veterans Integrated Service Network (VISN) 2, to Walgreens Specialty Pharmacy, LLC. The contract is for the delivery of the medication Jynarque (tolvaptan) 45/15mg tablets, which is used to treat autosomal dominant polycystic kidney disease. The contract has a ceiling value of $13,242.99 and a performance period ending on June 18, 2025. The...
- The U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price purchase order to Walgreens Specialty Pharmacy, LLC in the amount of $12,580.72. The contract is for the delivery of the medication Jynarque (tolvaptan) to treat autosomal dominant polycystic kidney disease. This contract was awarded to Walgreens Specialty Pharmacy as the prime contractor, with no set-aside designation mentioned. The contract period of performance runs through March 19,...
- This is a firm fixed price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Walgreens Specialty Pharmacy, LLC, a division of the Walgreens retail pharmacy chain. The $12,580.72 contract is for the supply of Jynarque 45mg/15mg tablets, a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease. The contract has a performance period from June 5, 2024 to September 5, 2024 and was not set aside for...
- This is a firm fixed-price purchase order contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Walgreens Specialty Pharmacy, LLC, a subsidiary of the Walgreens retail pharmacy chain. The contract, valued at $83,000.32, is for the supply of the pharmaceutical drug JYNARQUE (tolvaptan) to treat autosomal dominant polycystic kidney disease. The contract does not have a set-aside designation and has an ultimate completion date of September 30, 2021. Walgreens...
This federal contract award was issued by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Walgreens Specialty Pharmacy, LLC, a division of the larger Walgreens retail pharmacy chain. The $12,580.72 firm fixed price purchase order is for the delivery of the medication Jynarque (tolvaptan) 45mg/15mg tablets to VA facilities. Jynarque is used to treat autosomal dominant polycystic kidney disease. This contract does not have a set-aside designation and is part of Walgreens Specialty Pharmacy's broader role as a prime contractor providing specialized pharmaceuticals to multiple Veterans Integrated Service Networks (VISNs) within the VA system. The company's expertise in handling and delivering complex medications makes it a critical supplier in supporting the VA's healthcare services for veterans.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.6k | 8/20/24 |